Senolytics Ranked: Fisetin and Quercetin Lead Evidence-Based Longevity Stacks
Expert reviews rank fisetin and quercetin as top senolytics, with spermidine and resveratrol as supporting players in longevity supplement stacks.
Summary
A comprehensive review of popular longevity supplements evaluates fisetin, quercetin, spermidine, and resveratrol based on preclinical and emerging human evidence. Fisetin earns top marks as the most potent senolytic flavonoid tested, with mouse studies showing lifespan extension and early human pilots suggesting biological age reduction in adults over 50. Quercetin pairs well with fisetin for senolytic protocols and has stronger human meta-analytic data on inflammation and cardiovascular markers. Spermidine supports autophagy but remains early-stage in human evidence. Resveratrol activates sirtuins and works best in combination. The expert consensus favors intermittent senolytic dosing monthly rather than daily use, and cautions that most evidence remains animal-based. Supplement blends combining these compounds exist but lack comprehensive anti-aging coverage without additional ingredients like Ca-AKG.
Detailed Summary
Longevity supplement interest has surged, but separating evidence-based options from hype remains difficult for consumers and clinicians alike. This expert review evaluates four prominent compounds — fisetin, quercetin, spermidine, and resveratrol — across preclinical strength, human trial data, dosing protocols, and cost, offering a practical framework for building evidence-informed stacks.
Fisetin emerges as the standout recommendation. Preclinical studies, including a landmark EBioMedicine paper, show it extends both median and maximum lifespan in mice and clears senescent cells more potently than other flavonoids tested. Early human pilot data from 2024 suggest biological age reductions in adults over 50, and ongoing trials are exploring applications in Alzheimer's disease and long COVID. Recommended dosing is intermittent — 100 to 500mg for roughly one week per month — rather than daily.
Quercetin ranks as an essential companion senolytic, particularly when combined with fisetin or dasatinib. Unlike fisetin, quercetin benefits from stronger human evidence, including meta-analyses supporting reductions in inflammatory markers and cardiovascular risk. Bioavailability is a key consideration; pairing with piperine significantly improves absorption. Typical intermittent dosing is 1000mg on the same schedule as fisetin.
Spermidine and resveratrol play supporting roles. Spermidine induces autophagy — the cellular cleanup process — but human data remain limited, placing it in a lower evidence tier. Resveratrol activates SIRT1 and supports mitochondrial function, with strong preclinical backing but mixed clinical results; it is best used in combination, particularly alongside NMN.
The review's expert consensus recommends intermittent senolytic protocols monthly, with daily low-dose spermidine and resveratrol as adjuncts. Commercially available blends like Youth and Earth and SenoAid combine these compounds but vary in dosing completeness. Clinicians should note that the evidence base remains predominantly animal-derived, and human trial data, while promising, are still maturing.
Key Findings
- Fisetin is the most potent senolytic flavonoid tested preclinically, with early human data showing biological age reduction in adults over 50.
- Quercetin has stronger human meta-analytic evidence than fisetin, supporting reductions in inflammation and cardiovascular risk markers.
- Intermittent dosing — quercetin 1000mg plus fisetin 100–500mg for one week per month — is the expert-recommended senolytic protocol.
- Spermidine supports autophagy but remains Tier 3 evidence; human data are limited and doses in commercial blends are often low.
- Resveratrol works best in combination stacks, particularly paired with NMN, rather than as a standalone foundational supplement.
Methodology
This is an expert narrative review synthesizing preclinical and clinical literature on four longevity supplements, supplemented by product analysis of commercial supplement blends. Evidence is tiered by study type, with preclinical animal data, human pilot studies, and meta-analyses weighted accordingly. No systematic search protocol or PRISMA methodology is described in the available abstract.
Study Limitations
This summary is based on the abstract only, as the full article is not open access, which limits assessment of methodology, citation quality, and potential conflicts of interest. The underlying evidence for most compounds reviewed remains predominantly animal-based, with human trials that are early-stage, small, or ongoing. The review appears to be from a commercial health platform, which may introduce bias toward supplement-positive conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.